| 1.13 -0.01 (-0.88%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.42 | 1-year : | 1.48 |
| Resists | First : | 1.21 | Second : | 1.27 |
| Pivot price | 1.18  |
|||
| Supports | First : | 1.12 | Second : | 0.94 |
| MAs | MA(5) : | 1.15 |
MA(20) : | 1.18 |
| MA(100) : | 1.24 |
MA(250) : | 1.38 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 19.1 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 1.95 | Low : | 1.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PLRX ] has closed above bottom band by 14.5%. Bollinger Bands are 5.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.17 - 1.18 | 1.18 - 1.18 |
| Low: | 1.11 - 1.12 | 1.12 - 1.13 |
| Close: | 1.12 - 1.13 | 1.13 - 1.14 |
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Fri, 12 Jun 2026
Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike - Stock Titan
Fri, 12 Jun 2026
Pliant Therapeutics (PLRX) director receives 70,000-share stock option grant - Stock Titan
Fri, 12 Jun 2026
Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14 - Stock Titan
Fri, 12 Jun 2026
Director Darren Cline receives 70,000 PLRX stock options at $1.14 strike price - Stock Titan
Thu, 21 May 2026
Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Mon, 11 May 2026
Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 81.9 (%) |
| Shares Short | 3,440 (K) |
| Shares Short P.Month | 3,640 (K) |
| EPS | -1.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -53.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -0.62 |
| PEG Ratio | 0 |
| Price to Book value | 0.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|